# A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME

> **NCT06571045** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **EyeBiotech Ltd.** · enrollment: 984 (actual)

## Conditions studied

- Diabetic Macular Edema (DME)

## Interventions

- **DRUG:** Ranibizumab
- **DRUG:** EYE103

## Key facts

- **NCT ID:** NCT06571045
- **Lead sponsor:** EyeBiotech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-07
- **Primary completion:** 2026-09
- **Final completion:** 2027-12-31
- **Target enrollment:** 984 (ACTUAL)
- **Last updated:** 2025-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06571045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06571045, "A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06571045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*